In preclinical studies, Hirohashi et al. [154] reported that survivin-2B is abundantly expressed in several tumor cell lines and its derived peptide is recognized by CTLs that then recognize survivin-positive HLA-A24+ cancer cells. Here, BIRC5 is linked to neoplasm.